Effect of SMO16, a KOREAN Poly-Herbal Medicine, on Bone Mass in Ovariectomized Rat
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
The objective of this study was to explore the effect of SMO16, a Korean poly-herbal medicine, on bone mass in ovariectomized (OVX) rats. The loss of bone mass is known to be associated with hormone deficiency in OVX rats. In the present study, we successfully produced the osteoporosis animal-model by dissecting the ovary. To determine the protective effect of SMO16 in OVX rat, SMO16 was administered at a dose of 2.25 g/kg in saline solution for 8 weeks after OVX. Furthermore, we evaluated the direct effect of SMO16 by using a soft X-ray system and Masson’s trichrome staining, phloxine-tartrazine staining, and immunohistochemistry in vivo. SMO16 significantly regulated the expression of proteoglycan and osteopontin. These data suggest that SMO16 exerts a protective effect against osteoporosis via the activation of proteoglycan and osteopontin that are closely associated with bone balance. Moreover, these findings suggest that SMO16 can act as a potential therapeutic agent for the treatment of osteoporosis.
Abstract
The objective of this study was to explore the effect of SMO16, a Korean poly-herbal medicine, on bone mass in ovariectomized (OVX) rats. The loss of bone mass is known to be associated with hormone deficiency in OVX rats. In the present study, we successfully produced the osteoporosis animal-model by dissecting the ovary. To determine the protective effect of SMO16 in OVX rat, SMO16 was administered at a dose of 2.25 g/kg in saline solution for 8 weeks after OVX. Furthermore, we evaluated the direct effect of SMO16 by using a soft X-ray system and Masson’s trichrome staining, phloxine-tartrazine staining, and immunohistochemistry in vivo. SMO16 significantly regulated the expression of proteoglycan and osteopontin. These data suggest that SMO16 exerts a protective effect against osteoporosis via the activation of proteoglycan and osteopontin that are closely associated with bone balance. Moreover, these findings suggest that SMO16 can act as a potential therapeutic agent for the treatment of osteoporosis.
참고문헌 (10)
- Ferrari SL., "Osteoporosis: A Complex Disor-der of Aging with Multiple Genetic and Envi-ronmental Determinants", World Review of Nutrition and Dietetics, 95, pp.35~51 (2005)
- Sroga GE, "Effects of Bone Ma-trix Proteins on Fracture and Fragility in Os-teoporosis", Current Osteoporosis Reports, 10(2), pp.141~150 (2012)
- Sözen T, "An Overview and Management of Osteoporosis", European Journal of Rheumatology, 4(1), pp.46~56 (2017)
- Adler RA, "Managing Osteo-porosis in Patients on Long-term Bisphos-phonate Treatment: Report of a Task Force of the American Society for Bone and Min-eral Research", Journal of Bone and Mineral Research, 31(1), pp.16~35 (2016)
- Cao H, "Effect of Icariin on Fracture Healing in an Ovariectomized Rat Model of Osteoporosis", Experimental and Therapeutic Medicine, 13(5), pp.2399~2404 (2017)
- Wu J, "Combined Intervention of Exercise and Genistein Pre-vented Androgen Deficiency-induced Bone Loss in Mice", Journal of Applied Physiology, 94(1), pp.335~342 (2003)
- Das AK, "Gastroprotective Effect of Achyranthes Aspera Linn Leaf on Rats", Asian Pacific Jour-nal of Tropical Medicine, 5(3), pp.197~201 (2012)
- Winzenberg T, "How do Women Change Osteoporosis-preventive Behaviours in Their Children?", European Journal of Clinical Nutrition, 62(3), pp.379~385 (2008)
- Brown C., "Osteoporosis: Staying Strong", Nature, 550(7674), pp.15~17 (2017)
- McGreevy C, "Safety of Drugs Used in the Treatment of Osteoporosis", Therapeutic Advances in Drug Safety, 2(4), pp.159~172 (2011)